8-K: ADC Therapeutics Updates on ZYNLONTA Expansion & Financials

ADC Therapeutics SA provides an updated corporate presentation detailing ZYNLONTA's clinical progress, strategic reprioritization, and financial position with an expected cash runway to at least 2028.

Summary

• An updated corporate presentation was released on January 12, 2026.
• Preliminary unaudited FY2025 net revenue for ZYNLONTA is approximately $73 million, compared to $69 million in FY2024.
• The estimated cash balance is approximately $261 million as of December 31, 2025, with an expected cash runway at least to 2028.
• Strategic reprioritization included discontinuing the solid-tumor preclinical pipeline, a global workforce reduction of approximately 30%, and closing UK operations.
• The LOTIS-7 (ZYNLONTA + glofitamab) Phase 1b trial demonstrated an 89.8% Overall Response Rate (ORR) and 77.6% Complete Response (CR) rate in 49 efficacy-evaluable 2L+ LBCL patients.
• The LOTIS-5 (ZYNLONTA + rituximab) Phase 3 confirmatory trial completed enrollment in 2024, with topline data expected in Q2 2026.
• Investigator-initiated trials (IITs) for ZYNLONTA showed an 84.6% ORR and 69.2% CR in r/r MZL (26 evaluable patients) and a 98.2% ORR and 83.6% CR in r/r FL (55 evaluable patients).
• The company aims to establish ZYNLONTA as a backbone therapy in earlier lines of DLBCL and indolent lymphomas, targeting a potential annual US peak revenue opportunity of $600 million to $1 billion.

Sentiment

Score: 7

Explanation: The filing presents strong clinical data for ZYNLONTA in various lymphoma types and outlines a clear strategy for market expansion. Financials show stability with a good cash runway, supported by recent equity raises. However, the strategic reprioritization involved workforce reduction and discontinuation of preclinical programs, indicating a need for focused capital management. The overall tone is positive regarding future growth potential, but acknowledges inherent risks in drug development and commercialization.

Positives

• Preliminary FY2025 ZYNLONTA net revenue increased to ~$73M from $69M in FY2024.
• A strong estimated cash balance of ~$261M as of December 31, 2025, provides an expected cash runway at least to 2028.
• The LOTIS-7 trial (ZYNLONTA + glofitamab) demonstrated high efficacy with an 89.8% ORR and 77.6% CR rate in 2L+ LBCL, with a manageable safety profile.
• Investigator-initiated trials showed impressive CR rates for ZYNLONTA in r/r MZL (69.2%) and r/r FL (83.6%).
• Full enrollment was completed for the LOTIS-5 Phase 3 trial, with topline data anticipated in Q2 2026.
• Successful equity offerings raised $160M, contributing to financial stability.
• Strategic reprioritization focuses resources on ZYNLONTA expansion, streamlining operations.

Negatives

• A global workforce reduction of approximately 30% was implemented.
• Operations in the UK were closed.
• The remaining solid-tumor preclinical pipeline was discontinued.
• Significant cash is required to service indebtedness from Healthcare Royalty Management, Blue Owl, and Oaktree facilities.

Risks

• Changes to the preliminary unaudited Q4 and full year 2025 net product revenue and cash and cash equivalents.
• Uncertainty regarding future LOTIS-7 clinical trial results consistency, timing, publication, compendia inclusion, regulatory strategy, and commercial opportunity.
• Timing of PFS events and topline data release for LOTIS-5 and the trial results, and timing for sBLA submission and full FDA approval.
• Ability to grow ZYNLONTA revenue in the United States and achieve potential peak revenue.
• Ability of partners to commercialize ZYNLONTA in foreign markets, timing and amount of future revenue and payments from partnerships, and their ability to obtain regulatory approval.
• Timing and results of the Company's clinical trials.
• Timing, publication, and results of investigator-initiated trials, including those studying FL and MZL, and potential regulatory/compendia strategy and future opportunity.
• Timing and outcome of regulatory submissions for products or product candidates.
• Actions by the FDA or foreign regulatory authorities.
• Projected revenue and expenses.
• Indebtedness, including Healthcare Royalty Management, Blue Owl, and Oaktree facilities, and restrictions imposed by such indebtedness, the ability to comply with terms, repay indebtedness, and significant cash required for service.
• Ability to obtain financial and other resources for research, development, clinical, and commercial activities.
• Uncertainties of international trade policies, including tariffs, sanctions, trade barriers, and most favored nation drug pricing.

Future Outlook

The company aims to establish ZYNLONTA as a backbone therapy with a differentiated clinical profile across combinations in 2L+ DLBCL and provide significant patient benefit in indolent lymphomas, including FL and MZL. This strategy is expected to achieve a potential annual US peak revenue opportunity of $600 million to $1 billion with a highly leveraged cost structure, providing broader opportunities to invest in complementary hematology assets. Key milestones include topline LOTIS-5 data in Q2 2026, potential confirmatory approval in 2L+ DLBCL by 1H 2027, and ongoing assessment of regulatory and compendia strategies for MZL and FL.

Management Comments

• ADC Therapeutics: A Pioneer in ADCs with Significant Growth Opportunity from ZYNLONTA.
• Delivering on our strategy supported by an accomplished and multidisciplinary team with an expected cash runway at least to 2028.
• We believe LOTIS-7 has the potential to be the leading bispecific combination regimen for patients with access to complex therapies.
• LOTIS-7 provides a unique combination for r/r DLBCL without repeat exposure to polatuzumab and chemo.
• We believe LOTIS-5 has the potential to be the leading regimen for patients who will not receive complex therapies.
• ZYNLONTA combinations have the potential to unlock significant growth through: Doubling the addressable patient population (2L), Capturing higher market share with leading efficacy, Increasing average duration of therapy (3 cycles with mono to 5-6 with combo).

Industry Context

The r/r DLBCL market is segmented into complex therapies (CAR T, bispecifics) and broadly accessible outpatient therapies (ADCs, mAbs, chemo/other). ZYNLONTA, both as monotherapy and in combination, is positioned to disrupt both segments. LOTIS-7 (ZYNLONTA + glofitamab) aims to compete with CAR T-cell therapies and other bispecific combinations by offering a leading CR rate with a manageable toxicity profile and improved accessibility. LOTIS-5 (ZYNLONTA + rituximab) targets the broadly accessible segment, aiming for a high CR rate among ADCs, mAbs, and chemo/other options. The company's strategy aligns with the need for effective, accessible treatments across different patient needs in the evolving lymphoma treatment landscape.

Comparison to Industry Standards

• LOTIS-7 (Lonca + Glofit) achieved a 78% CR rate, which is higher than Yescarta (axi-cel) at 65% CR and Breyanzi (liso-cel) at 66% CR (CAR T-cell therapies).
• LOTIS-7's 78% CR rate also surpasses other bispecific combinations like Columvi (glofitamab) + GEMOX at 59% CR, Mosunetuzumab + Polatuzumab at 58% CR, and Epkinly (epcoritamab) + GEMOX at 61% CR.
• LOTIS-5 (Lonca + R) showed a 50% CR rate in its safety run-in, which is competitive with other broadly accessible therapies such as Adcetris (Brentuximab) + R2 at 45% CR, Polatuzumab + BR at 40% CR, and Monjuvi (Tafasitamab + Lenalidomide) at 37% CR.
• ZYNLONTA monotherapy (LOTIS-2) had a 25% CR rate, comparable to R-GEMOX (R-based Chemo) at 25% CR.
• In r/r MZL, ZYNLONTA IIT showed a 69% CR rate, which is higher than Zanubrutinib (68%), Len + Rituximab (R2) (65%), Acalabrutinib (53%), and Pirtobrutinib (50%).
• In r/r FL, ZYNLONTA + Rituximab IIT showed an 84% CR rate, which is competitive with CAR T-cell therapies like Axi-cel (79%), Liso-cel (94%), and Tisa-cel (69%), and other regimens like Epco+R2 (83%) and Tafa + R2 (49%).

Stakeholder Impact

• Shareholders: Potential for significant value creation through ZYNLONTA expansion and peak revenue targets, supported by a stable financial position and recent capital raise.
• Employees: Impacted by a global workforce reduction of approximately 30% as part of strategic reprioritization.
• Patients: Potential for new, highly effective treatment options for relapsed/refractory large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma, with manageable safety profiles and improved accessibility.
• Partners: Continued collaboration for commercialization of ZYNLONTA in foreign markets, with potential for future revenue and payments.
• Creditors: The company's indebtedness to Healthcare Royalty Management, Blue Owl, and Oaktree facilities requires significant cash to service, but the expected cash runway to 2028 provides confidence.

Next Steps

• Generate additional data and assess regulatory and compendia strategies for Marginal Zone Lymphoma (MZL).
• Generate additional data and assess regulatory and compendia strategies for Follicular Lymphoma (FL).
• Full enrollment of 100 patients at selected dose for LOTIS-7 (expected 1H 2026).
• Share topline results for LOTIS-5 in Q2 2026.
• Publication and potential LOTIS-7 compendia (expected 1H 2026).
• Publication and potential MZL compendia (expected 2H 2026).
• Potential confirmatory approval in 2L+ DLBCL (expected 1H 2027).
• Publication and potential LOTIS-5 compendia (expected 1H 2027).
• Publication and potential FL compendia (expected 2H 2027).

Key Dates

Recommendation

The company demonstrates strong clinical progress with ZYNLONTA, particularly the impressive CR rates in LOTIS-7 and IITs for indolent lymphomas, which could significantly expand its market opportunity. Financial stability is bolstered by recent equity raises and a projected cash runway to 2028. However, the strategic reprioritization, including workforce reduction and pipeline cuts, indicates a focused but narrower path. While the potential peak revenue is substantial, the company still faces significant execution risks in achieving regulatory approvals, market penetration, and managing its substantial debt. The stock is likely to react positively to the strong clinical data and financial outlook, but a 'hold' recommendation is prudent given the ongoing development risks and the need to see sustained revenue growth and successful market expansion before a 'buy' recommendation.

Keywords

ADC Therapeutics, ZYNLONTA, Loncastuximab Tesirine, DLBCL, Follicular Lymphoma, Marginal Zone Lymphoma, Antibody-Drug Conjugate, Oncology, Hematology, Clinical Trials, SEC Filing, Biotechnology, Pharmaceuticals, Corporate Presentation, Financial Update